Researcher.Life Logo

Expert Review of Anticancer Therapy : Impact Factor & More

eISSN: 1744-8328pISSN: 1473-7140

Aims and Scope of Expert Review of Anticancer Therapy

Expert Review of Anticancer Therapy is a monthly peer-reviewed medical journal covering all clinical aspects of cancer therapy. It was established in 2001 and is published by Taylor & Francis under the academic publishing division of Informa. The current Editor-in-Chief is Gertjan J L Kaspers who is Head of Pediatric Oncology at VU University Medical Center Amsterdam. According to Journal Citation Reports, the journal has a 2019 impact factor of 3.573. Less

Key Metrics

CiteScore
6.7
Eigenfactor
0.001 - 0.005
H-Index
79
Impact Factor
< 5
SJR
Q2Oncology
SNIP
1.08
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Review of Anticancer Therapy

Expert Review of Anticancer Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2000
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Review of Anticancer Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Review of Anticancer Therapy

Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state of the art
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Optic glioma in children: clinical presentation, diagnosis, and management
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis
  • 2 Sep 2026
  • Expert Review of Anticancer Therapy
Complications following small-molecule inhibitors for non-small cell lung cancer
  • 2 Sep 2026
  • Expert Review of Anticancer Therapy
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer
  • 2 Sep 2026
  • Expert Review of Anticancer Therapy
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state of the art
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Frailty is not ECOG: why performance status alone is no longer enough in anticancer therapy
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Optic glioma in children: clinical presentation, diagnosis, and management
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis
  • 2 Sep 2026
  • Expert Review of Anticancer Therapy
Complications following small-molecule inhibitors for non-small cell lung cancer
  • 2 Sep 2026
  • Expert Review of Anticancer Therapy
Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer
  • 2 Sep 2026
  • Expert Review of Anticancer Therapy

FAQs on Expert Review of Anticancer Therapy